Clinical trials: Rituximab, completed
Lymphocytic Leukemia, Chronic
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)
This open-label, randomized, 3-arm study will evaluate the efficacy and safety of obinutuzumab (RO5072759) in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with…
- Trial name
- NCT01010061
- Testing
- obinutuzumab, rituximab, chlorambucil
- Where
- 261 sites in United States, Argentina and 24 more
- Volunteers
- 787 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Lymphoma
Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00324779
- Testing
- rituximab
- Where
- 38 sites in Germany, Switzerland
- Volunteers
- 79 people
- Sponsor
- University Hospital Erlangen
B-cell Lymphoma, Indolent B-cell Lymphoma
High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas
The purpose of this clinical trial is to see if increased doses of rituximab are safe and effective for the initial treatment of indolent B-cell lymphomas.
- Trial name
- NCT00895661
- Testing
- rituximab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid
Treatment and Natural History Study of Lymphomatoid Granulomatosis
This study will evaluate the response and long-term effects of alpha-interferon in patients with lymphomatoid granulomatosis (LYG).
- Conditions
- Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid, Non-Hodgkins Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00001379
- Testing
- Interferon, Rituxan and EPOCH, Tumor biopsy
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis
Rituximab for Anti-cytokine Autoantibody-Associated Diseases
Background: Healthy people have white blood cells that protect them against bacteria, viruses, and fungi. However, some people have diseases which cause the body to make white blood cells that do not work properly.
- Trial name
- NCT01842386
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphoma, Hodgkin Lymphoma (Category)
Rituximab in Treating Patients With Hodgkin's Lymphoma
Phase 2 trial to study the effectiveness of rituximab in treating patients who have lymphocyte-predominant Hodgkin's lymphoma.
- Conditions
- Lymphoma, Hodgkin Lymphoma (Category), Nodular Lymphocyte Predominant Hodgkin Lymphoma
- Trial name
- NCT00003820
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Ranjana Advani
Follicular Lymphoma
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma.
- Trial name
- NCT02213263
- Testing
- PF-05280586, MabThera®
- Where
- 423 sites in United States, Austria and 28 more
- Volunteers
- 394 people
- Sponsor
- Pfizer
Graft vs Host Disease
Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease
The purpose of this study is to determine whether low-doses alemtuzumab and rituximab combination are effective in the treatment of chronic graft-versus-host disease (GVHD) after first-line therapy failure.
- Trial name
- LowAR (NCT01042509)
- Testing
- Alemtuzumab and rituximab
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma
Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of lenalidomide when given after combination chemotherapy with or without rituximab and stem cell transplant and to see how well it works in treating patients with…
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT01035463
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine
- Where
- 3 sites in United States
- Volunteers
- 74 people
- Sponsor
- University of Nebraska
Anti-NMDAR Encephalitis
Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis
The purpose of the study is to assess the efficacy of immunoadsorption therapy (IA) on improving the neurological status of severe pediatric anti-NMDAR encephalitis patients.
- Trial name
- IANMDAR (NCT03274375)
- Testing
- IA session, Rituximab
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lymphoma, Follicular
A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma
This is a Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the statistical equivalence of efficacy, safety and immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in…
- Trial name
- RAMO-2 (NCT02809053)
- Testing
- SAIT101, MabThera®
- Where
- 25 sites in United States, Australia and 12 more
- Volunteers
- 315 people
- Sponsor
- Archigen Biotech Limited
Leukemia, Lymphoma
Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00425802
- Testing
- anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Untreated T-cell Angioimmunoblastic Lymphoma
A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma
To evaluate the efficacy and the safety of a front-line treatment combining CHOP regimen and rituximab in patients aged 60 to 80 years with previously untreated AIL.
- Trial name
- NCT00169156
- Testing
- Rituximab, Prednisone, Doxorubicine
- Where
- 4 sites in France
- Volunteers
- 27 people
- Sponsor
- Lymphoma Study Association
Immune Thrombocytopenic Purpura
Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP
The purpose of this study is to determine the response rate and response duration with the combination of low-dose rituximab and high-dose dexamethasone in the treatment of adult immune thrombocytopenic purpura.
- Trial name
- NCT01107951
- Testing
- Rituximab and dexamethasone
- Where
- Mexico
- Volunteers
- 21 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Rheumatoid Arthritis
Observational Safety Study of Rituximab in Patients Diagnosed With Rheumatoid Arthritis (RA) Who Did Not Respond Adequately to TNF-alpha Blocker
This multi-center, observational, retrospective-prospective cohort study will investigate the safety of rituximab (MabThera) by collecting data from daily clinical practice on the use of rituximab and its relative clinical…
- Trial name
- NCT02322801
- Where
- 54 sites in Italy
- Volunteers
- 209 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00005601
- Testing
- rituximab, cisplatin, cytarabine
- Where
- 21 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Hodgkin's Lymphoma
IMPACT Non Hodgkins Lymphoma (NHL) Study
This is multi-center, international observational study of subjects receiving CHOP-14 or CHOP-21 (with or without Rituximab) for the treatment of NHL.
- Trial name
- NCT00903812
- Testing
- No intervention
- Volunteers
- 1,837 people
- Sponsor
- Amgen
Acute Lymphoblastic Leukemia, in Relapse
CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children
Relapsed acute lymphoblastic leukaemia (ALL) has a poorer outcome than newly diagnosed ALL patients with only about 40% overall survival after re-treatment.
- Trial name
- NCT04224571
- Testing
- Bortezomib Injection, rituximab injection
- Where
- Hong Kong
- Volunteers
- 208 people
- Sponsor
- Chinese University of Hong Kong
Diffuse Large B-Cell Lymphoma
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
This study evaluates the addition of selinexor (KPT-330) to RICE chemotherapy in the treatment of relapsed and refractory aggressive B-Cell Lymphoma, with the goal of improved response rates (as compared to RICE chemotherapy…
- Trial name
- KPT-330+RICE (NCT02471911)
- Testing
- KPT-330, Rituximab, Etoposide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Weill Medical College of Cornell University
Non-Hodgkin Lymphoma, Follicular Lymphoma
A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma
This study is a Phase 1/2 open-label three part study in patients with relapsed indolent Non-Hodgkin's lymohoma (NHL) (Parts A and C) or relapsed/refractory follicular lymphoma (FL) (Part B).
- Trial name
- LYMRIT-37-01 (NCT01796171)
- Testing
- 10 MBq/kg Betalutin, 15 MBq/kg Betalutin, 20 MBq/kg Betalutin
- Where
- 96 sites in United States, Australia and 22 more
- Volunteers
- 191 people
- Sponsor
- Nordic Nanovector
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.